PatternsRadar
Sign in

ALIVUSAlivus Life Sciences Limited

NSE
1,436.90INR-13.00 (-0.90%)Close · 20 Nov 2026
29 Oct 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹17,669 CrMarket cap
26.4P/E (TTM)
51.2%Delivery

Filings & corporate actions

22 results filed
CSV
Next results · Q3 FY27
Expected 22 Jan 2027 – 8 Feb 2027
Estimate: filed 22–39 days after quarter end, last 5 times
Dividend
₹5.00 per share · last 1 Sept 2026
2026
  • 29 OctresultsResults · Q2 FY27 · standalone+1.3%NSE
  • 14 OctshareholdingShareholding · 30 Sept 2026+0.3%NSE
  • 1 SeptdividendDividend · ₹5.00 per share+2.7%
  • 30 JulresultsResults · Q1 FY27 · standalone+5.9%NSE
  • 13 JulshareholdingShareholding · 30 Jun 20260.0%NSE
  • 14 MayresultsResults · Q4 FY26 · standalone-1.8%NSE
  • 14 AprshareholdingShareholding · 31 Mar 2026+1.8%NSE
  • 22 JanresultsResults · Q3 FY26 · standalone+2.6%NSE
  • 19 JanshareholdingShareholding · 31 Dec 2025-1.8%NSE

Reaction to results · all yearsrose on day 0 in 10 of 22 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY2729 Oct 2026+1.3%+6.0%—10.8×
Q1 FY2730 Jul 2026+5.9%+21.4%+23.2%2.8×
Q4 FY2614 May 2026-1.8%-2.4%-1.2%1.8×
Q3 FY2622 Jan 2026+2.6%+6.2%+5.7%3.3×
Q2 FY266 Nov 2025+2.8%+1.6%-0.8%1.6×
Q1 FY261 Aug 2025-3.5%-7.3%-6.3%1.6×
Q4 FY2515 May 2025-5.3%-7.4%-15.9%2.1×
Q3 FY2523 Jan 2025-1.5%+2.9%-9.6%2.0×
Q2 FY2524 Oct 2024-9.9%+1.0%+2.6%2.7×
Q1 FY2525 Jul 2024-2.9%+0.9%+18.0%1.3×
Q4 FY2425 Apr 2024+8.6%+10.7%+10.9%5.5×
Q3 FY2423 Jan 2024+1.2%+8.4%+11.1%1.0×
Q2 FY2420 Oct 2023-0.7%+0.2%+0.3%0.5×
Q1 FY2421 Jul 2023+0.1%+5.6%+0.8%1.7×
Q4 FY2328 Apr 2023+5.2%+12.8%+13.5%10.3×
Q3 FY2327 Jan 2023-0.8%-3.6%-3.7%1.1×
Q2 FY2322 Oct 2022+3.2%+7.1%+2.9%0.3×
Q1 FY235 Aug 2022-0.6%-1.2%-2.6%1.0×
Q4 FY2221 Apr 2022-0.1%-1.6%-9.9%1.0×
Q3 FY228 Feb 2022-2.3%-8.1%-19.0%2.5×
Q2 FY2211 Nov 2021+2.9%-1.1%-2.7%3.2×
Q1 FY2213 Aug 2021-3.2%-11.8%-6.0%—
Average+0.0%+1.8%+0.5%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+16.0%
Profit YoY+51.3%
Interest cost YoY+26.3%
Revenue QoQ+6.5%
Profit QoQ+22.9%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+10.3%+4.7%+7.2%———
Profit+25.8%+9.8%+12.5%———

Key data

Open1,449.90
Day range1,420.40 – 1,460.00
52-week range819.00 – 1,574.00
From 52w high-8.7%
RSI (14)52.3
ATR (14)59.89
Volume1.43L
Avg volume (20D)5.05L
Rel volume0.28×
Volatility (1Y)30.0%
Turnover₹20.6Cr
Traded value (NSE)₹20.6Cr
VWAP1,438.92
SMA 50 / 2001,389.10 / 1,166.47
Price band20%

Delivery percentage

Latest · 20 Nov 202651.2%
20-day avg51.7%
1-year avg53.5%
Percentile (own history)35th
Range6.1–94.3%
Sessions1,308

Over the last 20 sessions ALIVUS settled 51.7% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 53.5%. The latest session ranks higher than 35% of the 1,308 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.35%
Dividend, trailing 12M₹5.00
Paid every year for2 yr
Shareholders1.23L · -2.2% QoQ
Net bulk deals, 30D-1.70%
Block deals, 30D₹389.9Cr
Last bulk buy14 days ago

Performance returns

1D1W1M3M6M1Y
Price-0.90%-1.62%+13.23%+4.88%+36.01%+58.83%

Valuation

Market cap₹17,669 Cr
Market cap (NSE)₹17,641 Cr
Free-float cap₹4,444 Cr
P/E (TTM)26.4
P/E (NSE)26.6
EPS (TTM)54.47
P/B4.9
Net margin (TTM)24.9%
Other income / PBT8.9%
ROE20.2%
Debt / equity0.00
Shares outstanding12.28Cr
Listed6 Aug 2021

Ownership

Promoter74.85%
Promoter Δ QoQ-0.02 pp
Public25.15%
FII5.93%
DII7.03%
Pledged0.00%

Quarterly results · standalone

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)672.9689.1640.4682.0
YoY chg+4.8%+6.1%+6.4%+16.0%
Net profit (₹ Cr)150.3162.7160.1196.7
YoY chg+9.7%+14.7%+31.7%+51.3%
Net margin22.3%23.6%25.0%28.8%
EPS12.2213.2213.0115.98

Shareholding over time

By quarter

30 Sept 2026 · promoter 74.85% · public 25.15%
5 Aug 2021: promoter 82.84%30 Sept 2021: promoter 82.84%31 Dec 2021: promoter 82.84%31 Mar 2022: promoter 82.85%30 Jun 2022: promoter 82.85%30 Sept 2022: promoter 82.85%31 Dec 2022: promoter 82.85%31 Mar 2023: promoter 82.85%30 Jun 2023: promoter 82.85%30 Sept 2023: promoter 82.85%31 Dec 2023: promoter 82.85%31 Mar 2024: promoter 82.85%30 Jun 2024: promoter 82.85%30 Sept 2024: promoter 75.00%31 Dec 2024: promoter 75.00%31 Mar 2025: promoter 74.99%30 Jun 2025: promoter 74.94%30 Sept 2025: promoter 74.91%31 Dec 2025: promoter 74.91%31 Mar 2026: promoter 74.87%30 Jun 2026: promoter 74.87%30 Sept 2026: promoter 74.85%
2021-082026-09
  • Promoter
  • Public and others
Promoter
74.85%
Public
25.15%
Promoter change
-0.02 pp
Filed
14 Oct 2026
FII
5.93%
DII
7.03%
Promoter pledged
0.00%

Who the public is

Mutual funds
5.29%

-0.36 pp QoQ

Insurance
0.24%

-0.03 pp QoQ

FPI
5.93%

+0.39 pp QoQ

Retail ≤ ₹2L
9.00%

-0.30 pp QoQ

HNI > ₹2L
1.11%

+0.36 pp QoQ

NRI
0.64%

-0.05 pp QoQ

Bodies corporate
1.17%

-0.10 pp QoQ

Shareholders
1,22,777

-2.2% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
Nirma LimitedPromoter · Corporate74.85%
Quant Mutual Fund - Quant Small Cap FundMutual fund2.85%
Government Pension Fund GlobalFPI2.33%
Massachusetts Institute of TechnologyFPI1.23%
Old Bridge Focused FundMutual fund1.07%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Dividends

since 22 Nov 2021 CSV
Financial yearPaymentsDeclaredAdjusted
FY2026-271₹5.00₹5.00
FY2025-261₹5.00₹5.00
FY2023-241₹22.50₹22.50
FY2022-232₹31.50₹31.50
FY2021-221₹10.50₹10.50
Ex-dateRecord dateDeclaredAdjusted
1 Sept 2026—₹5.00₹5.00
1 Sept 2025—₹5.00₹5.00
17 Oct 2023—₹22.50₹22.50
24 Mar 2023—₹21.00₹21.00
15 Sept 2022—₹10.50₹10.50
22 Nov 2021—₹10.50₹10.50

Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.

52-week highs & lows

Loading…

Each session the stock traded past its previous 52-week high or low, from NSE's daily report; the previous figure is the record it broke. Prices as published, not split-adjusted.

Book closures & record dates

Loading…

NSE's corporate-action calendar: who held the stock on the record date, or through the book-closure window, was entitled to the dividend, bonus, split or rights named.

Insider trades

Insiders net, 30d
₹0
Insiders net, 90d
₹0
Promoters net, 90d
₹0
Insider buyers, 90d
0
Last promoter buy
5.0 years ago
Disclosures on record
8
2 open-market of the newest 8
By year
BroadcastPersonSideSharesValuePriceHolding before → afterStakeRegulation
17 Nov 2021GLENN SALDANHAPromoterBuy7.5K₹48.3L643.19295 → 7.8K0.00%0.00 pp7(2)told 17 Nov 2021
17 Nov 2021GLENN SALDANHAPromoterBuy295₹1.9L640.77— → 2950.00%7(2)told 17 Nov 2021

SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.

How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session

Bulk & block deals · 6 Nov 2026

CSV
12 of 17 deals
By year
DateDealClientQuantityPriceValue
6 Nov 2026Sell · block, also bulkNIRMA LIMITED28.46L1,370.00₹389.9Cr
6 Nov 2026Buy · block, also bulkPARAM CAPITAL7.30L1,370.00₹100.0Cr
6 Nov 2026Buy · blockBANDHAN MUTUAL FUND6.00L1,370.00₹82.2Cr
6 Nov 2026Buy · blockSETU SECURITIES PRIVATE LIMITED4.10L1,370.00₹56.2Cr
6 Nov 2026Buy · blockSUBHKAM VENTURES I PVT LTD2.50L1,370.00₹34.3Cr
6 Nov 2026Buy · blockSANSHI FUND - I2.00L1,370.00₹27.4Cr
6 Nov 2026Buy · blockBANDHAN MUTUAL FUND2.00L1,370.00₹27.4Cr
6 Nov 2026Buy · blockNORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBAL1.83L1,370.00₹25.1Cr
6 Nov 2026Buy · blockHELIOS MUTUAL FUND1.16L1,370.00₹15.9Cr
6 Nov 2026Buy · blockHELIOS MUTUAL FUND1.01L1,370.00₹13.9Cr
6 Nov 2026Buy · blockBANDHAN MUTUAL FUND38.1K1,370.00₹5.2Cr
6 Nov 2026Buy · blockBANDHAN MUTUAL FUND17.8K1,370.00₹2.4Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.

Exchange surveillance

20 Nov 2026

No surveillance measure applies to ALIVUS.

Price band: 20% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

Standalone
₹ crore, as filed
By year
 Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27Q2 FY27
Revenue from operations572.8536.6588.6506.9641.8649.5601.8588.0672.9689.1640.4682.0
Other income1.73.15.58.510.510.19.014.713.922.822.419.9
Total income574.5539.7594.1515.4652.3659.6610.8602.7686.8711.9662.8701.9
Total expenses413.8410.0443.9388.0467.2468.3447.9428.6462.8496.1450.6439.9
└ Finance costs0.40.40.40.30.51.31.31.31.51.31.31.3
└ Depreciation13.214.514.415.115.216.017.118.419.720.220.621.8
Profit before tax160.7129.7150.2127.5185.1191.3163.0174.1198.4215.8212.2262.0
Tax expense41.931.738.832.148.249.441.444.148.153.152.165.2
Net profit118.897.9111.595.3137.0141.9121.5130.0150.3162.7160.1196.7
EPS9.697.999.107.7811.1811.579.9110.6012.2513.2313.0416.02
Net margin20.73%18.25%18.94%18.80%21.34%21.84%20.19%22.11%22.33%23.60%25.00%28.85%
PBT margin28.05%24.17%25.52%25.15%28.85%29.45%27.08%29.62%29.48%31.32%33.14%38.41%
Tax rate26.09%24.48%25.80%25.22%26.03%25.84%25.43%25.33%24.26%24.62%24.57%24.90%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 29 Oct 2026.

Balance sheet & cash flow · half-yearly

Standalone
₹ crore, as filed
By year

Balance sheet

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Total assets2,702.12,953.02,850.43,084.93,411.53,638.33,982.94,341.9
Current assets1,850.32,076.71,916.02,096.12,335.22,475.92,649.42,864.8
└ Cash & equivalents283.8442.9301.4446.171.118.92.025.4
└ Other bank balances25.60.10.20.20.20.20.20.1
└ Current investments0.00.00.00.0477.6633.6780.4986.2
└ Trade receivables806.8807.5765.4775.1969.71,002.81,073.0988.2
└ Inventories604.2669.5666.6689.2673.9722.5691.9782.8
Total equity2,138.22,391.72,332.32,538.52,817.43,015.43,332.13,631.3
└ Attributable to owners2,138.22,391.72,332.32,538.52,817.43,015.43,332.13,631.3
└ Share capital24.524.524.524.524.524.524.524.6
Borrowings0.00.00.00.00.00.00.00.0
└ Current0.00.00.00.00.00.00.00.0
└ Non-current0.00.00.00.00.00.00.00.0
Trade payables396.6385.2368.7398.2390.5409.9372.4427.3
Current liabilities504.4499.0438.8463.7470.2489.3508.0563.7
Total liabilities563.9561.2518.1546.4594.1623.0650.8710.7
Net debt(309.4)(443.1)(301.6)(446.3)(548.9)(652.8)(782.5)(1,011.7)
Debt / equity0.000.000.000.000.000.000.000.00
Current ratio3.674.164.374.524.975.065.215.08

Cash flow, year to date

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow313.4216.2413.5219.6391.5260.7565.4459.7
└ Capex(170.2)(62.7)(129.0)(85.6)(166.2)(113.0)(307.1)(189.5)
Free cash flow143.2153.5284.5133.9225.3147.7258.4270.2
Investing cash flow(154.1)(55.2)(116.5)(73.1)(615.6)(252.4)(570.2)(370.9)
Financing cash flow(387.6)(1.9)(279.4)(1.8)(6.2)(60.5)(64.3)(65.4)
└ Dividends paid(385.9)0.0(275.7)0.00.0(61.3)(61.3)(61.4)
└ Buybacks0.00.00.00.00.00.00.00.0
Net change in cash(228.3)159.117.6144.7(230.4)(52.1)(69.1)23.5

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

ALIVUS at a glance

  • ALIVUS closed at ₹1,436.9 on 20 Nov 2026, -0.90% on the day, +58.8% over one year, 8.7% below its 52-week high of ₹1,574.
  • Delivery was 51.2% of traded quantity on 20 Nov 2026, the 35th percentile of its own 1,308 sessions with a reading (20-session average 51.7%, 1-year average 53.5%).
  • Market capitalisation is ₹17,669 crore at a trailing P/E of 26.4 (trailing EPS ₹54.47).
  • Q2 FY27 results (standalone, filed 29 Oct 2026): revenue ₹682 crore (+16.0% year on year), net profit ₹197 crore (+51.3%); the price moved +1.3% on the first session after.
  • Promoters held 74.85% at 30 Sept 2026, down 0.02 percentage points on the previous filing.
  • Q3 FY27 results are expected between 22 Jan 2027 and 8 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE03Q201024
SeriesEQ
Listed6 Aug 2021
IPO price720.00 · band Rs.695 to Rs.720
IPO listing6 Aug 2021
Former symbolsGLS (until 20 Jan 2025)
Former namesGlenmark Life Sciences Limited (until 20 Jan 2025)
NSE market cap · 17 Nov 2026₹17,803 Cr
Free-float market cap (NSE)₹4,451 Cr
Shares outstanding (NSE)12.30Cr
History from6 Aug 2021
Sessions1,312
Turnover rank#352

Sector history

  1. to 16 Aug 2026Index industry · Healthcare
  2. from 16 Aug 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

NSE’s own classification, by the snapshot it changed on.

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.